CD40

Across TCGA pan-cancer cohorts, CD40 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD40 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD40 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD40 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where CD40 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.709	1.000	<.001	36	view →
UCEC	DFS	Median	All	0.833	0.970	.003	24	view →
LSCC	DFS	Tertile	II,III,IV	0.458	0.944	<.001	19	view →
LUAD	DFS	Quartile	All	1.000	0.831	<.001	17	view →
PDAC	OS	Quartile	III,IV	0.689	0.986	.011	9	view →
HNSC	DFS	Median	II,III,IV	0.907	0.984	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD40–CCRCC (OS)

Open the CCRCC breakdown →